Healthcare provider profile · identity verified

Erin M Griffith, NP-C

Nurse Practitioner · CHARLOTTE, MI · NPI 1912352915

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	306	72
Potassium Chloride	Potassium Chloride	197	41
Levothyroxine Sodium	Levothyroxine Sodium	195	52
Furosemide	Furosemide	188	43
Eliquis	Apixaban	145	32
Omeprazole	Omeprazole	135	29
Metoprolol Succinate	Metoprolol Succinate	128	32
Lisinopril	Lisinopril	120	30
Amlodipine Besylate	Amlodipine Besylate	114	32
Gabapentin	Gabapentin	103	32
Trazodone Hcl	Trazodone Hcl	100	23
Losartan Potassium	Losartan Potassium	92	25
Pantoprazole Sodium	Pantoprazole Sodium	88	21
Escitalopram Oxalate	Escitalopram Oxalate	84	20
Buspirone Hcl	Buspirone Hcl	78	15
Sertraline Hcl	Sertraline Hcl	78	20
Metformin Hcl	Metformin Hcl	76	23
Ropinirole Hcl	Ropinirole Hcl	75	15
Metoprolol Tartrate	Metoprolol Tartrate	73	17
Tamsulosin Hcl	Tamsulosin Hcl	70	16
Duloxetine Hcl	Duloxetine Hcl	68	18
Famotidine	Famotidine	67	12
Mirtazapine	Mirtazapine	64	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	63	33
Clopidogrel	Clopidogrel Bisulfate	59	13
Albuterol Sulfate Hfa	Albuterol Sulfate	57	23
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	52	12
Carvedilol	Carvedilol	50	13
Jardiance	Empagliflozin	50	suppressed
Spironolactone	Spironolactone	49	suppressed
Donepezil Hcl	Donepezil Hcl	48	11
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	45	suppressed
Citalopram Hbr	Citalopram Hydrobromide	44	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	43	suppressed
Meloxicam	Meloxicam	43	13
Bupropion Xl	Bupropion Hcl	42	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	42	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	42	11
Alendronate Sodium	Alendronate Sodium	40	suppressed
Aripiprazole	Aripiprazole	40	suppressed
Bumetanide	Bumetanide	40	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	40	12
Fluoxetine Hcl	Fluoxetine Hcl	39	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	39	suppressed
Metformin Hcl Er	Metformin Hcl	38	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	38	suppressed
Hydralazine Hcl	Hydralazine Hcl	36	suppressed
Pravastatin Sodium	Pravastatin Sodium	36	suppressed
Trulicity	Dulaglutide	36	suppressed
Olanzapine	Olanzapine	35	suppressed
Clonidine Hcl	Clonidine Hcl	34	suppressed
Montelukast Sodium	Montelukast Sodium	34	11
Carbidopa-Levodopa	Carbidopa/Levodopa	33	suppressed
Januvia	Sitagliptin Phosphate	33	suppressed
Tizanidine Hcl	Tizanidine Hcl	33	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	31	suppressed
Pregabalin	Pregabalin	31	suppressed
Memantine Hcl	Memantine Hcl	30	suppressed
Ezetimibe	Ezetimibe	29	suppressed
Mirabegron Er	Mirabegron	29	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	28	suppressed
Spiriva Respimat	Tiotropium Bromide	28	11
Hydroxyzine Hcl	Hydroxyzine Hcl	27	16
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	26	suppressed
Divalproex Sodium	Divalproex Sodium	26	suppressed
Allopurinol	Allopurinol	25	suppressed
Glipizide Er	Glipizide	25	suppressed
Lamotrigine	Lamotrigine	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Celecoxib	Celecoxib	22	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	11
Levetiracetam	Levetiracetam	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Enalapril Maleate	Enalapril Maleate	21	suppressed
Risperidone	Risperidone	21	suppressed
Ondansetron Odt	Ondansetron	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	suppressed
Azithromycin	Azithromycin	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Simvastatin	Simvastatin	18	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	17	suppressed
Clonazepam	Clonazepam	17	suppressed
Entresto	Sacubitril/Valsartan	17	suppressed
Prednisone	Prednisone	17	13
Rexulti	Brexpiprazole	17	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	17	suppressed
Atenolol	Atenolol	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Latanoprost	Latanoprost	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Pen Needles	Pen Needle, Diabetic	16	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	16	suppressed
Topiramate	Topiramate	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Clindamycin Hcl	Clindamycin Hcl	15	13
Nystatin	Nystatin	15	12
Torsemide	Torsemide	15	suppressed
Finasteride	Finasteride	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Methotrexate	Methotrexate Sodium	13	suppressed
Baclofen	Baclofen	12	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error